Breast Cancer: Molecular Pathogenesis and Targeted Therapy.

Area of Science:

• Oncology
• Cancer Research
• Precision Medicine

Background:

• Breast cancer (BC) is a leading cause of cancer mortality in women, driven by complex factors including genetics and signaling pathway alterations.
• Tumor heterogeneity, treatment resistance, and recurrence necessitate the development of novel therapeutic strategies for effective breast cancer management.

Purpose of the Study:

• To review innovative therapeutic approaches for breast cancer.
• To highlight advancements in targeted therapies, immunomodulatory strategies, and emerging technologies shaping BC treatment.

Main Methods:

• Review of current oncology research focusing on targeted therapies (e.g., CDK 4/6 inhibitors, PARP inhibitors) and immunotherapies (e.g., immune checkpoint inhibitors).
• Exploration of novel strategies including targeting intratumoral heterogeneity, liquid biopsy for resistance detection, AI-based drug discovery, patient-derived organoids, and adaptive trial designs.

Main Results:

• Targeted therapies and immunotherapies show promise in overcoming BC resistance.
• Innovative approaches like liquid biopsies and AI-driven drug discovery are crucial for personalized treatment strategies.
• Emerging methods address challenges like treatment resistance and improve therapeutic efficacy.

Conclusions:

• Combining molecular insights with precision therapeutics offers significant potential to improve breast cancer treatment efficacy and patient outcomes.
• Novel strategies are essential for overcoming treatment resistance and recurrence in breast cancer.
• Advancements in BC treatment are moving towards more personalized and effective patient care.